Novo Nordisk A/S (NVO): Is This Incompetence? Wonders Jim Cramer

We recently published 12 Stocks Jim Cramer Recently Discussed As He Commented On A “Sea Of Green”. ABC is one of the stocks Jim Cramer recently discussed.

Novo Nordisk A/S (NYSE:NVO), the Danish healthcare company, hasn’t performed well in 2025. The shares have lost a whopping 43% year-to-date and sank by 22% in July after the firm cut its full-year growth guidance to 8% to 14% from an earlier 13% to 21%. Crucially, Novo Nordisk A/S (NYSE:NVO)’s downbeat guidance was on the back of worries about its weight loss drug Wegovy. Investors weren’t pleased that the firm expects to struggle in the hot weight loss drug market. As for Cramer, he believes incompetence might have a role to play in Novo Nordisk A/S (NYSE:NVO)’s woes:

“Now that is, I felt, that borders on incompetence, given the fact that we know all of the different uses that are coming. But this company has been challenged, they seem way out of their league.”

Copyright: dolgachov / 123RF Stock Photo

Previously, the CNBC TV host discussed Novo Nordisk A/S (NYSE:NVO)’s exposure to sectoral tariffs by President Trump:

“[If market should start thinking about sectoral tariffs after Trump’s latest remarks] I mean when I heard it first I said okay, so they put a tariff on Novo Nordisk. It’s really good for Eli Lilly. Now that’s not necessarily what we’re talking about but remember this price differential right now. . CVS, Eli Lilly versus Novo. So for Wegovy versus Zepbound. Be interesting to see what happens, I think it’s very bullish for Eli Lilly.”

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.